Status:
COMPLETED
Dose-Effect Relation of Salivary Gland Irradiation
Lead Sponsor:
The Netherlands Cancer Institute
Conditions:
HNSCC
Eligibility:
All Genders
18+ years
Brief Summary
Optimization of radiotherapy to reduce xerostomia is difficult, because many gland locations cannot be seen with current imaging modalities and biological dose-effect are currently insufficiently unde...
Detailed Description
Primary objective of this prospective observational study is to determine the gland-based dose-effect relation between conventionally fractionated radiotherapy (RT) and long-term loss of acinar cells,...
Eligibility Criteria
Inclusion
- HNSCC of the head-neck area, cTx-4 N0-3 M0
- Accepted for EBRT in a conventionally fractionated schedule of 6-7 weeks.
Exclusion
- Age \<18y
- Pregnancy or lactation
- Participation in conflicting studies, e.g. with non-standard treatment and/or imaging
- Inability to provide informed consent
Key Trial Info
Start Date :
November 21 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 15 2021
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT03367780
Start Date
November 21 2017
End Date
July 15 2021
Last Update
August 19 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
The Netherlands Cancer Institute- Antoni van Leeuwenhoek (NKI-AVL)
Amsterdam, North Holland, Netherlands, 1066CX
2
University Medical Center Groningen
Groningen, Netherlands, 9700RB
3
University Medical Center Utrecht
Utrecht, Netherlands, 3584CX